Mylan NV won't be testifying at a Senate Judiciary Committee hearing Nov. 30 over pricing of the EpiPen anti-allergy medication.
Mylan's lawyers, Latham & Watkins LLP, informed the committee in a letter Nov. 18 to its chairman, U.S. Sen. Charles Grassley. Grassley has been at the forefront of criticism against the sharp price increases of the Mylan (Nasdaq: MYL) product over the past nine years, and scheduled the hearing to look into a $465 million settlement between Mylan and the U.S. Justice Department…
Mylan NV won't be testifying at a Senate Judiciary Committee hearing Nov. 30 over pricing of the EpiPen anti-allergy medication.
Mylan's lawyers, Latham & Watkins LLP, informed the committee in a letter Nov. 18 to its chairman, U.S. Sen. Charles Grassley. Grassley has been at the forefront of criticism against the sharp price increases of the Mylan (Nasdaq: MYL) product over the past nine years, and scheduled the hearing to look into a $465 million settlement between Mylan and the U.S. Justice Department…